Tags

Type your tag names separated by a space and hit enter

Association between the COMT Val158Met polymorphism and fibromyalgia susceptibility and fibromyalgia impact questionnaire score: a meta-analysis.
Rheumatol Int 2015; 35(1):159-66RI

Abstract

The aim of this study was to explore whether the catechol-O-methyltransferase (COMT) Val158Met polymorphism is associated with susceptibility to fibromyalgia and fibromyalgia impact questionnaire (FIQ) score in fibromyalgia patients. We conducted a meta-analysis of the associations of the COMT Val158Met polymorphism with fibromyalgia risk as well as FIQ score in fibromyalgia patients. A total of 993 fibromyalgia patients and 778 controls from 10 studies on the COMT Val158Met polymorphism and 538 fibromyalgia patients from 5 studies on the COMT Val158Met polymorphism and FIQ score were included in this meta-analysis. The meta-analysis revealed an association between fibromyalgia and the COMT Met/Met + Val/Met genotype in all study subjects (odds ratio (OR) 1.635, 95 % confidence interval (CI) 1.029-2.597, p = 0.037). However, stratification by ethnicity indicated no association between the Met/Met + Val/Met genotype and fibromyalgia in the European and Turkish populations (OR 1.202, 95 % CI 0.876-1.649, p = 0.255; OR 2.132, 95 % CI 0.764-5.949, p = 0.148, respectively). Analysis using other genetic models showed no association between the COMT Val158Met polymorphism and fibromyalgia. The meta-analysis also revealed that the FIQ score was significantly higher in individuals with the COMT Met/Met genotype than in those with the Val/Val genotype [weighted mean difference (WMD) = 14.39, 95 % CI 3.316-25.48, p = 0.011] and the Val/Met genotype (WMD = 5.108, 95 % CI 2.212-4.891, p = 0.021). This meta-analysis identified an association between fibromyalgia risk and the COMT Val158Met polymorphism as well as the FIQ score in fibromyalgia patients.

Authors+Show Affiliations

Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 126-1, Anam-dong 5-ga, Seongbuk-gu, Seoul, 136-705, Korea, lyhcgh@korea.ac.kr.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24951880

Citation

Lee, Young Ho, et al. "Association Between the COMT Val158Met Polymorphism and Fibromyalgia Susceptibility and Fibromyalgia Impact Questionnaire Score: a Meta-analysis." Rheumatology International, vol. 35, no. 1, 2015, pp. 159-66.
Lee YH, Kim JH, Song GG. Association between the COMT Val158Met polymorphism and fibromyalgia susceptibility and fibromyalgia impact questionnaire score: a meta-analysis. Rheumatol Int. 2015;35(1):159-66.
Lee, Y. H., Kim, J. H., & Song, G. G. (2015). Association between the COMT Val158Met polymorphism and fibromyalgia susceptibility and fibromyalgia impact questionnaire score: a meta-analysis. Rheumatology International, 35(1), pp. 159-66. doi:10.1007/s00296-014-3075-2.
Lee YH, Kim JH, Song GG. Association Between the COMT Val158Met Polymorphism and Fibromyalgia Susceptibility and Fibromyalgia Impact Questionnaire Score: a Meta-analysis. Rheumatol Int. 2015;35(1):159-66. PubMed PMID: 24951880.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Association between the COMT Val158Met polymorphism and fibromyalgia susceptibility and fibromyalgia impact questionnaire score: a meta-analysis. AU - Lee,Young Ho, AU - Kim,Jae-Hoon, AU - Song,Gwan Gyu, Y1 - 2014/06/21/ PY - 2014/04/10/received PY - 2014/06/12/accepted PY - 2014/6/22/entrez PY - 2014/6/22/pubmed PY - 2016/1/7/medline SP - 159 EP - 66 JF - Rheumatology international JO - Rheumatol. Int. VL - 35 IS - 1 N2 - The aim of this study was to explore whether the catechol-O-methyltransferase (COMT) Val158Met polymorphism is associated with susceptibility to fibromyalgia and fibromyalgia impact questionnaire (FIQ) score in fibromyalgia patients. We conducted a meta-analysis of the associations of the COMT Val158Met polymorphism with fibromyalgia risk as well as FIQ score in fibromyalgia patients. A total of 993 fibromyalgia patients and 778 controls from 10 studies on the COMT Val158Met polymorphism and 538 fibromyalgia patients from 5 studies on the COMT Val158Met polymorphism and FIQ score were included in this meta-analysis. The meta-analysis revealed an association between fibromyalgia and the COMT Met/Met + Val/Met genotype in all study subjects (odds ratio (OR) 1.635, 95 % confidence interval (CI) 1.029-2.597, p = 0.037). However, stratification by ethnicity indicated no association between the Met/Met + Val/Met genotype and fibromyalgia in the European and Turkish populations (OR 1.202, 95 % CI 0.876-1.649, p = 0.255; OR 2.132, 95 % CI 0.764-5.949, p = 0.148, respectively). Analysis using other genetic models showed no association between the COMT Val158Met polymorphism and fibromyalgia. The meta-analysis also revealed that the FIQ score was significantly higher in individuals with the COMT Met/Met genotype than in those with the Val/Val genotype [weighted mean difference (WMD) = 14.39, 95 % CI 3.316-25.48, p = 0.011] and the Val/Met genotype (WMD = 5.108, 95 % CI 2.212-4.891, p = 0.021). This meta-analysis identified an association between fibromyalgia risk and the COMT Val158Met polymorphism as well as the FIQ score in fibromyalgia patients. SN - 1437-160X UR - https://www.unboundmedicine.com/medline/citation/24951880/Association_between_the_COMT_Val158Met_polymorphism_and_fibromyalgia_susceptibility_and_fibromyalgia_impact_questionnaire_score:_a_meta_analysis_ L2 - https://dx.doi.org/10.1007/s00296-014-3075-2 DB - PRIME DP - Unbound Medicine ER -